Item response analysis of the Positive and Negative Syndrome Scale

Santor, Darcy A.; Ascher-Svanum, Haya; Lindenmayer, Jean-Pierre; Obenchain, Robert L.
January 2007
BMC Psychiatry;2007, Vol. 7, p66
Academic Journal
Background: Statistical models based on item response theory were used to examine (a) the performance of individual Positive and Negative Syndrome Scale (PANSS) items and their options, (b) the effectiveness of various subscales to discriminate among individual differences in symptom severity, and (c) the appropriateness of cutoff scores recently recommended by Andreasen and her colleagues (2005) to establish symptom remission. Methods: Option characteristic curves were estimated using a nonparametric item response model to examine the probability of endorsing each of 7 options within each of 30 PANSS items as a function of standardized, overall symptom severity. Our data were baseline PANSS scores from 9205 patients with schizophrenia or schizoaffective disorder who were enrolled between 1995 and 2003 in either a large, naturalistic, observational study or else in 1 of 12 randomized, double-blind, clinical trials comparing olanzapine to other antipsychotic drugs. Results: Our analyses show that the majority of items forming the Positive and Negative subscales of the PANSS perform very well. We also identified key areas for improvement or revision in items and options within the General Psychopathology subscale. The Positive and Negative subscale scores are not only more discriminating of individual differences in symptom severity than the General Psychopathology subscale score, but are also more efficient on average than the 30-item total score. Of the 8 items recently recommended to establish symptom remission, 1 performed markedly different from the 7 others and should either be deleted or rescored requiring that patients achieve a lower score of 2 (rather than 3) to signal remission. Conclusion: This first item response analysis of the PANSS supports its sound psychometric properties; most PANSS items were either very good or good at assessing overall severity of illness. These analyses did identify some items which might be further improved for measuring individual severity differences or for defining remission thresholds. Findings also suggest that the Positive and Negative subscales are more sensitive to change than the PANSS total score and, thus, may constitute a "mini PANSS" that may be more reliable, require shorter administration and training time, and possibly reduce sample sizes needed for future research.


Related Articles

  • Assessment of strategies for switching patients from olanzapine to risperidone: A randomized, open-label, rater-blinded study. Ganguli, Rohan; Brar, Jaspreet S.; Mahmoud, Ramy; Berry, Sally A.; Pandina, Gahan J. // BMC Medicine;2008, Vol. 6, Special section p1 

    Background: In clinical practice, physicians often need to change the antipsychotic medications they give to patients because of an inadequate response or the presence of unacceptable or unsafe side effects. However, there is a lack of consensus in the field as to the optimal switching strategy...

  • The impact of duration of untreated psychosis and premorbid functioning on outcome of first inpatient treatment in schizophrenic and schizoaffective patients. Bottlender, Ronald; Sato, Tetsuya; Jäger, Markus; Groll, Constanze; Strauß, Anton; Möller, Hans-Jürgen // European Archives of Psychiatry & Clinical Neuroscience;2002, Vol. 252 Issue 5, p226 

    Objective: The aim of the study was to investigate the association between the duration of untreated psychosis, premorbid functioning and outcome from first inpatient treatment in schizophrenic or schizoaffective patients. Method: The data of 196 first-hospitalized patients with a schizophrenic...

  • Levels of expectation for work activity in schizophrenia: Clinical... Bell, Morris; Lysaker, Paul // Psychiatric Rehabilitation Journal;Winter1996, Vol. 19 Issue 3, p71 

    Assesses the effects of expectation in a work activity program for 150 participants with schizophrenia and schizoaffective disorder who were assigned to a high-expectation and self-regulation condition. Rehabilitation programs imposing sanctions.

  • Greater weight increases with olanzapine than with risperidone.  // Reactions Weekly;7/2/2005, Issue 1058, p4 

    Presents the results of a study that compared the effects of olanzapine and risperidone use in patients with schizophrenia or schizoaffective disorders. Drug which caused a significant increase in body weight and visceral adiposity after 24 weeks; Patients who experienced impaired secretory...

  • Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder. Stauffer, Virginia L.; Sniadecki, Jennifer L.; Piezer, Kevin W.; Gatz, Jennifer; Kollack-Walker, Sara; Hoffmann, Vicki Poole; Conley, Robert; Durell, Todd // BMC Psychiatry;2010, Vol. 10, p89 

    Background: To examine potential differences in efficacy and safety of treatment with olanzapine in patients with schizophrenia of white and black descent. Methods: A post-hoc, pooled analysis of 6 randomized, double-blind trials in the treatment of schizophrenia, schizophreniform disorder, or...

  • Association of autonomic dysfunction and clozapine. Cohen, Hagit; Loewenthal, Uri; Matar, Michael; Kotler, Moshe // British Journal of Psychiatry;Aug2001, Vol. 179, p167 

    Background Antipsychotic medications cause a wide range of adverse effects and have been associated with sudden death in psychiatric patients. Aims To supply power spectral analysis of heart rate variability as a tool to examine the arrythmogenic effects of neuroleptics. Method Heart rate...

  • Monitoring and Prevalence Rates of Metabolic Syndrome in Military Veterans with Serious Mental Illness. Khatana, Sameed Ahmed M.; Kane, Joshua; Taveira, Tracey H.; Bauer, Mark S.; Wen-Chih Wu // PLoS ONE;2011, Vol. 6 Issue 4, p1 

    Background: Cardiovascular disease is the leading cause of mortality among patients with serious mental illness (SMI) and the prevalence of metabolic syndrome-a constellation of cardiovascular risk factors-is significantly higher in these patients than in the general population. Metabolic...

  • An antipsychotic's side effects derail a patient's symptom management.  // Clinical Advisor;Aug2010, Vol. 13 Issue 8, p45 

    The article presents a case study of a 30 year-old man with history of schizoaffective disorder. It states that he suffers from auditory hallucinations, paranoid delusions, and periods of insomnia and underwent six months of treatment using stabilized olanzapine. It also mentions that the...

  • Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Iran, Pierre V.; Tollefson, Gary D.; Sanger, Todd M.; Yili Lu; Berg, Paul H.; Beasley Jr., Charles M. // British Journal of Psychiatry;Jan99, Vol. 174, p15 

    Background The effectiveness of antipsychotic monotherapy in schIzoaffective disorder is limited, and further constrained by safety concerns. Aims We aimed to compare the efficacy, tolerability and safety profile of the new pharmaceutical, olanzapine, with haloperidol. Method Data were assessed...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics